- CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE
-
The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.
- -
-
Page/Page column 437
(2020/05/28)
-
- SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
-
The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.
- -
-
Page/Page column 81; 82; 83
(2018/01/15)
-
- Discovery of potent c-MET inhibitors with new scaffold having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine headgroups
-
Cellular mesenchymal-epithelial transition factor (c-MET) is closely linked to human malignancies, which makes it an important target for treatment of cancer. In this study, a series of 3-methoxy-N-phenylbenzamide derivatives, N-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl) benzamide derivatives and N1-(3-fluoro-4-methoxyphenyl)-N3-(4-fluorophenyl) malonamide derivatives were designed and synthesized, some of them were identified as c-MET inhibitors. Among these compounds with new scaffolds having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine head groups, compound 11c, 11i, 13b, 13h exhibited both potent inhibitory activities against c-MET and high anticancer activity against tested cancer cell lines in vitro. In addition, kinase selectivity assay further demonstrated that both 13b and 13h are potent and selective c-MET inhibitors. Molecular docking supported that they bound well to c-MET and VEGFR2, which demonstrates that they are potential c-MET RTK inhibitors for cancer therapy.
- Jiang, Yingnan,Zhang, Ke,Gao, Suyu,Wang, Guihua,Huang, Jian,Wang, Jinhui,Chen, Lixia
-
-
- AROMATIC HETEROCYCLIC COMPOUND
-
The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.
- -
-
Paragraph 1293; 1294
(2015/05/05)
-
- Ruthenium-catalyzed asymmetric hydrogenation of 3-oxoglutaric acid derivatives: A study of unconventional solvent and substituent effects
-
A series of 3-oxoglutaric acid derivatives have been hydrogenated in different solvents in the presence of [RuCl(benzene)(S)-SunPhos]Cl (SunPhos=(2,2,2′,2′-tetramethyl-[4,4′-bibenzo[d][1,3]dioxole] -5,5′-diyl)bis(diphenylphosphine)). Unlike simple β-keto acid derivatives, these advanced analogues can be readily hydrogenated in uncommon solvents such as THF, CH2Cl2, acetone, and dioxane with high enantioselectivities. Two possible catalytic cycles have been proposed to explain the different reactivities of these 1,3,5-tricarbonyl substrates in the tested solvents. The C-2 and C-4 substituents had notable but irregular influence on the reactivity and enantioselectivity of the reactions. More pronounced solvent effects were observed: the ee values increased from around 20 % in EtOH or THF to 90 % in acetone. Inversion of the product configuration was observed when the solvent was changed from EtOH to THF or acetone, and a mixed solvent system can lead to better enantioselectivity than a single solvent. Pronounced solvent effects: 3-Oxoglutaric acid derivatives have been hydrogenated in various solvents with high enantioselectivities (see scheme). Inversions of the product configuration were observed when the solvent was changed. Mixed solvent systems can give better enantioselectivities than a single solvent.
- Li, Wanfang,Tao, Xiaoming,Ma, Xin,Fan, Weizheng,Li, Xiaoming,Zhao, Mengmeng,Xie, Xiaomin,Zhang, Zhaoguo
-
supporting information
p. 16531 - 16539
(2013/02/22)
-
- Importance of ligand bioactive conformation in the discovery of potent indole-diamide inhibitors of the hepatitis C virus NS5B
-
Significant advances have led to receptor induced-fit and conformational selection models for describing bimolecular recognition, but a more comprehensive view must evolve to also include ligand shape and conformational changes. Here, we describe an example where a ligand's "structural hinge" influences potency by inducing an "L-shape" bioactive conformation, and due to its solvent exposure in the complex, reasonable conformation-activity-relationships can be qualitatively attributed. From a ligand design perspective, this feature was exploited by successful linker hopping to an alternate "structural hinge" that led to a new and promising chemical series which matched the ligand bioactive conformation and the pocket bioactive space. Using a combination of X-ray crystallography, NMR and modeling with support from binding-site resistance mutant studies and photoaffinity labeling experiments, we were able to derive inhibitor-polymerase complexes for various chemical series.
- Laplante, Steven R.,Gillard, James R.,Jakalian, Araz,Aubry, Norman,Coulombe, Rene,Brochu, Christian,Tsantrizos, Youla S.,Poirier, Martin,Kukolj, George,Beaulieu, Pierre L.
-
supporting information; experimental part
p. 15204 - 15212
(2010/12/29)
-
- VIRAL POLYMERASE INHIBITORS
-
An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula (I): wherein wherein A, B, R2, R3, L, M1, M2, M3, M4, Y1, Y0, Z and Sp are as defined in claim 1, or a salt thereof, as an inhibitor of HCV NS5B polymerase.
- -
-
-
- CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS
-
The present invention relates to compounds of formula (I) or pharmaceutically acceptable derivatives thereof, useful in the treatment or prophylaxis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
- -
-
-
- Structure-Activity Relationship Studies of Illudins: Analogues Possessing a Spiro-cyclobutane Ring
-
Bicyclic and tricyclic analogues of anticancer sesquiterpene illudin S have been synthesized. These contain a spiro-cyclobutane instead of spiro-cyclopropane structure. The cytotoxicity of the former is less than that of the corresponding cyclopropane-containing compounds.
- McMorris, Trevor C.,Cong, Qiang,Kelner, Michael J.
-
p. 9648 - 9653
(2007/10/03)
-
- Viral polymerase inhibitors
-
An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: wherein R1 is selected from: H, haloalkyl, (C1-6)alkyl, (C2-6)alkenyl, (C3-7)cycloalkyl, (C2-6)alkynyl, (C5-7)cycloalkenyl, 6 or 10-membered aryl, Het all optionally substituted; R2 is selected from (C1-6)alkyl, (C3-7)cycloalkyl, (C6-10)bicycloalkyl, 6- or 10-membered aryl, or Het all optionally substituted; B is N or CR5, wherein R5 is H, halogen, haloalkyl, (C1-6)alkyl, (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; X is N or CR5; D is N or CR5; each of Y1 and Y2 is independently O or S; Z is O, N, or NRz wherein Rz is H, (C1-6)alkyl, (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; R3 and R4 are each independently H, (C1-6)alkyl, first (C3-7)cycloalkyl or 6- or 10-membered aryl, Het (C1-6)alkyl-6- or 10-membered aryl, (C1-6)alkyl-Het; or each R3 and R4 are independently covalently bonded together to form second (C3-7)cycloalkyl, or heterocycle, all optionally substituted; or when Z is N, either R3 or R4 are independently covalently bonded thereto to form a nitrogen-containing heterocycle; R7 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; or R7 is covalently bonded to either of R3 or R4 to form a heterocycle; A is (C1-6) alkyl-CONHR8 wherein R8 is-6- or 10-membered aryl, or Het; or A is a 6- or 10-membered aryl, or Het said aryl or Het being optionally substituted; or a salt or a derivative thereof; such compounds being potent inhibitors of HCV NS5B polymerase.
- -
-
-
- Efficient synthesis of a key intermediate of DV-7751 via optical resolution or microbial reduction
-
Two efficient and practical methods of synthesis of the C-10 substituent of DV-7751 (1), a novel quinolone carboxylic acid, were established. The first method utilizes an optical resolution of racemic 8-amino-6-benzyl-6- azaspiro[3.4]octane (13), while th
- Miyadera, Akihiko,Satoh, Koji,Imura, Akihiro
-
p. 563 - 565
(2007/10/03)
-
- Synthesis and antibacterial activity of novel pyridobenzoxazine analogues
-
A series of novel LVFX (7) analogues bearing 4,4-dialkyl-3- aminopyrrolidines at the C-10 position of pyridobenzoxazine was synthesized and their antibacterial activities, pharmacokinetics and acute toxicities in animals were evaluated. Non-alkylated pyrr
- Kawakami, Katsuhiro,Atarashi, Shohgo,Kimura, Youichi,Takemura, Makoto,Hayakawa, Isao
-
p. 1710 - 1715
(2007/10/03)
-
- Optically active pyridonecarboxylic acid derivatives
-
N1 -(1,2-cis-2-halogenocyclopropyl)-substituted pyridonecarboxylic acid derivatives represented by the following formula (I) the terms of which are defined in the specification and the salts thereof are disclosed: STR1 These compounds have pate
- -
-
-
- Antihypercholesterolemic compounds
-
Novel 3-hydroxy-3-methylglutaryl-Coenzyme A(HMG-CoA) reductase inhibitors, which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II) STR1 and pharmaceutically acceptable salts of the compound (II) in which Z is hydrogen are disclosed.
- -
-
-
- A NOVEL RING EXPANSION OF 1-CARBOETHOXY-1,1-TRIMETHYLENE-3-DIAZO-2-PROPANONE
-
The title compound undergoes an unusual thermal cyclobutyl to cyclopentyl rearrangement initiated by the intramolecular reaction of ketene moiety produced in situ with the pendant functionality.
- Miller, R. D.,Theis, W.
-
p. 2447 - 2450
(2007/10/02)
-